Cocrystal Pharma (FRA:8CC) Tariff Resilience Score: 8/10 (As of Jul. 07, 2026)


FRA:8CC Cocrystal Pharma Inc FRA:8CC
31 GF Score
Price €0.89
GF Value €2.43
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cocrystal Pharma Tariff Resilience Score?

Cocrystal Pharma FRA:8CC +0.57% 31 Tariff Resilience Score is 8 as of Jul. 07, 2026. GuruFocus rates FRA:8CC with a GF Score™ of 31/100 and a GF Value™ of €2.43 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,369 Biotechnology companies, Cocrystal Pharma ranks better than 98.69% on this metric.

Cocrystal Pharma has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Cocrystal Pharma has Cocrystal Pharma's focus on pharmaceuticals, which often enjoy tariff exemptions, reduces its vulnerability. The company has a global research network, minimizing reliance on any single market. Historical tariff changes have had little impact on its operations.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cocrystal Pharma might have Highly Resilient.

Cocrystal Pharma  (FRA:8CC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cocrystal Pharma Tariff Resilience Score Related Terms

FRA:8CC vs HOOK, LNAI, CYCN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Cocrystal Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cocrystal Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Tariff Resilience Score falls into.


FRA:8CC
31GF Score
Cocrystal Pharma Inc FRA:8CC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Cocrystal Pharma (FRA:8CC) has a Tariff Resilience Score of 8 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Cocrystal Pharma ranks #18 out of 1369 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Cocrystal Pharma's Tariff Resilience Score too high?
Cocrystal Pharma's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Cocrystal Pharma's value of 8 is 100% above this industry median. Based on the distribution chart, Cocrystal Pharma ranks #18 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cocrystal Pharma has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's Tariff Resilience Score compare to HOOK and LNAI?
According to the Biotechnology industry distribution chart, Cocrystal Pharma ranks #18 out of 1369 companies for Tariff Resilience Score. This places Cocrystal Pharma in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Cocrystal Pharma's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cocrystal Pharma's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cocrystal Pharma's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Cocrystal Pharma (FRA:8CC) is currently considered Possible Value Trap. The stock's GF Value™ is €2.43, compared to a current price of €0.89 — trading 63.6% below its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Cocrystal Pharma's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Cocrystal Pharma (FRA:8CC), the current Tariff Resilience Score is 8 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cocrystal Pharma (FRA:8CC) Overvalued in 2026?

Based on GuruFocus' analysis, Cocrystal Pharma stock appears to be undervalued. The current stock price of €0.89 is trading 63.6% below its estimated GF Value™ of €2.43. GuruFocus considers Cocrystal Pharma to be Possible Value Trap.

Key valuation signals for FRA:8CC:

  • Tariff Resilience Score: 8
  • GF Value™: €2.43 vs. price of €0.89 (63.6% below fair value)
  • GF Score™: 31/100 with 3 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1369)

No single metric tells the full story. See the FRA:8CC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cocrystal Pharma Business Description

Other Exchanges COCP:USA
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
31GF Score

Get the complete analysis for FRA:8CC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.89
Price
€2.43
GF Value